Experience in treatment and prevention of respiratory diseases relapses in children with the use of the phytotherapeutic complex «Alpicol»: feedback of doctors in Ukraine


  • О.К. Koloskova Bukovynian State Medical University, Chernivtsi, Ukraine, Ukraine https://orcid.org/0000-0002-4402-8756
  • A.L. Kosakovskyi Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine https://orcid.org/0000-0001-7194-420X
  • T.M. Bilous Bukovynian State Medical University, Chernivtsi, Ukraine, Ukraine
  • I.B. Horbatiuk Bukovynian State Medical University, Chernivtsi, Ukraine, Ukraine
  • L.I. Romanchuk Bukovynian State Medical University, Chernivtsi, Ukraine, Ukraine




ecurrent respiratory diseases, treatment and prevention, children, phytocomplexes


Infectious and inflammatory diseases of the respiratory tract in children are the «leaders» among all pathologies of childhood. Optimization of therapeutic and prophylactic approaches for infectious and inflammatory pathologies of the respiratory system by reducing the frequency of unreasonable antibiotic therapy and eliminating polypragmatic use is a relevant problem of modern pediatrics and otolaryngology. According to WHO guidelines, modern standardized herbal medicines are not inferior in efficiency to synthetic ones.

The aim — to analyze the results of assessment by doctors of the preventive and therapeutic efficacy of the remedy «Alpicol» on the basis of a questionnaire, as well as clinical examination of patients before using the medication and after completion of the course of treatment.

Materials and methods. The advantages of «Alpicol» were analyzed through a questionnaire offered by first contact practitioners to children in order to receive feedback on the assessment of the preventive and therapeutic efficacy of this medication. Doctors from 9 regions of Ukraine were involved, and 6,093 questionnaires of children of different ages were analyzed.

Results. The frequency of registration of a pronounced paediatric pain (3 scores) with the use of the «Alpicol» medication significantly decreased (23.7 times), a moderate manifestation of the disease (2 scores), was 17 times less at the same time, mild manifestations of paediatric pain remained at the same level. Patients with a comorbid pathology of the respiratory tract in the form of recurrent lesions of the upper and lower airways during the 2nd visit received a zero score (no symptoms) significantly less frequently than children with pathology of the upper respiratory tract with 62.6% of cases versus 72.2% of observations, respectively (p<0.05). As a result of the use of the course of «Alpicol» medication, a statistically significant decrease in the severity of the catarrhal symptom complex was achieved, since the proportion of the course of disease, assessed by the maximum number of scores, decreased by 29.6 times, moderate (score 2) — 13.3 times, and zero scores appeared 5.7 times more often. At the same time, the proportion of patients with a mild course of catarrh practically did not change.

Conclusions. «Alpicol» has a multi;vector efficacy against the complex of symptoms that accompany infectious and inflammatory exacerbations of recurrent respiratory diseases. This is manifested by a decrease in the severity of clinical manifestations of the disease, as well as in an increase in cases of clinical stabilization of the patient's condition, which demonstrates the therapeutic and prophylactic effect of the drug «Alpicol» on the course of recurrent respiratory diseases in children.

The study was carried out in accordance with the principles of the Declaration of Helsinki. The study protocol was adopted by the Local Ethics Committee of all institutions indicated in this research. The informed consent of parents and children was obtained.

The authors declare that they have no conflicts of interest.


Abaturov OIe, Rusakova OO. (2012). Klinichni osoblyvosti perebihu ta stan mistsevoho imunitetu v ditei rannoho viku, yaki khvoriiut na hostryi obstruktyvnyi bronkhit. Perynatologiya i pediatriya. 1: 106-108.

Adachi Y, Okazaki M, Ohno N, Yadomae T. (1994). Enhancement of cytokine production by macrophages stimulated with (l→3)-β-D-glucan, grifolan (GRN), isolated from Grifola frondosa. Biologic. Pharma. Bul. 17: 1554-1560. https://doi.org/10.1248/bpb.17.1554; PMid:7537572

Antypkin YuH, Arabska LP, Smirnova OA et al. (2003). Suchasni pidkhody do diahnostyky, profilaktyky retsydyvuiuchykh i khronichnykh bronkhitiv u ditei. Kyiv: 122.

Ayeka PA. (2018, Apr 22). Potential of Mushroom Compounds as Immunomodulators in Cancer Immunotherapy: A Review. Evid Based Complement Alternat Med: 7271509. https://doi.org/10.1155/2018/7271509; PMid:29849725 PMCid:PMC5937616

Botstein D, Fink GR. (2011, Nov). Yeast: an experimental organism for 21st Century biology. Genetics. 189 (3): 695-704. https://doi.org/10.1534/genetics.111.130765; PMid:22084421 PMCid:PMC3213361

Brown GD, Gordon S Nature. (2001, Sep 6). Immune recognition. A new receptor for beta-glucans. 413 (6851): 36-37. https://doi.org/10.1038/35092620; PMid:11544516

Careddu D, Pettenazzo A. (2018, Mar 8). Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children. Int J Gen Med. 11: 91-98. https://doi.org/10.2147/IJGM.S154198; PMid:29563828 PMCid:PMC5849386

Chen C, Zuckerman DM, Brantley S, Sharpe M, Childress K, Hoiczyk E, Pendleton AR. (2014, Jan 16). Sambucus nigra extracts inhibit infectious bronchitis virus at an early point during replication. BMC Vet Res. 10: 24. https://doi.org/10.1186/1746-6148-10-24; PMid:24433341 PMCid:PMC3899428

Duman-Scheel M. (2019). Saccharomyces cerevisiae (Baker's Yeast) as an Interfering RNA Expression and Delivery System. Curr Drug Targets. 20 (9): 942-952. https://doi.org/10.2174/1389450120666181126123538; PMid:30474529 PMCid:PMC6700756

Elder MJ, Webster SJ, Chee R, Williams DL, Hill Gaston JS, Goodall JC. (2017). β-Glucan Size Controls Dectin-1-Mediated Immune Responses in Human Dendritic Cells by Regulating IL-1β Production. Front Immunol. 8: 791. https://doi.org/10.3389/fimmu.2017.00791; PMid:28736555 PMCid:PMC5500631

Enshasy H, Hatti-Kaul R. (2013). Mushroom immunomodulators: unique molecules with unlimited applications. Trends Biotechnol. 31: 668-677. https://doi.org/10.1016/j.tibtech.2013.09.003; PMid:24125745

Geller A, Yan J. (2020, Jul 14). Could the Induction of Trained Immunity by β-Glucan Serve as a Defense Against COVID-19? 11: 1782. doi: https://doi.org/10.3389/fimmu.2020.01782; PMid:32760409 PMCid:PMC7372085

Gonzalez-Navajas JM, Lee J, David M, Raz E. (2012). Immunomodulatory functions of type I interferons. Nat Rev Immunol. 12: 125-135. https://doi.org/10.1038/nri3133; PMid:22222875 PMCid:PMC3727154

Harnett J, Oakes K, Care J, Leach M, Brown D, Cramer H, Pinder TA, Steel A, Anheyer D. (2020, Dec). The effects of Sambucus nigra berry on acute respiratory viral infections: A rapid review of clinical studies. Adv Integr Med. 7 (4): 240-246. Epub 2020 Aug 22. https://doi.org/10.1016/j.aimed.2020.08.001; PMid:32864330 PMCid:PMC7443157

Huang C, Wang Y, Li X, Ren L, Zhao J. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395: 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5

Jekabsone A, Sile I, Cochis A, Makrecka-Kuka M, Laucaityte G, Makarova E, Rimondini L, Bernotiene R, Raudone L, Vedlugaite E, Baniene R, Smalinskiene A, Savickiene N, Dambrova M. (2019, Nov 19). Investigation of Antibacterial and Antiinflammatory Activities of Proanthocyanidins from Pelargonium sidoides DC Root Extract. Nutrients. 11 (11): 2829. https://doi.org/10.3390/nu11112829; PMid:31752295 PMCid:PMC6893413

Kak V, Sundareshan V, Modi J, Khardori NM. (2012). Immunotherapies in infectious diseases. Med Clin North Am. 96: 455-474. https://doi.org/10.1016/j.mcna.2012.04.002; PMid:22703851

Kramarov S, Кoloskova O, Bilous T, Іvanova L, Kaminska T, Nezgoda I, Stoieva T, Kharchenko Y, Garas M, Yevtushenko V, Seriakova I, Stanislavchuk L, Lobortas Y. (2021). Peculiarities of the course of coronavirus disease COVID-19 in children of various ages in certain regions of Ukraine. Medical Science. 25 (110): 985-998. https://doi.org/10.22141/2312-413X.9.2.2021.236219

Kumar D, Arya V, Kaur R, Bhat ZA, Gupta VK, Kumar V. (2012). A review of immunomodulators in the Indian traditional health care system. J Microbiol Immunol Infect. 45: 165-184. https://doi.org/10.1016/j.jmii.2011.09.030; PMid:22154993

Labro MT. (2012). Immunomodulatory effects of antimicrobial agents. Part I: antibacterial and antiviral agents. Expert Rev Anti-Infect Ther. 10: 319-340. https://doi.org/10.1586/eri.12.11; PMid:22397566

Lull C, Wichers HJ, Savelkoul H. (2005). Antiinflammatory and immunomodulating properties of fungal metabolites. Mediat Inflamm: 63-80. https://doi.org/10.1155/MI.2005.63; PMid:16030389 PMCid:PMC1160565

Moradali MF, Mostafavi H, Ghods S, Hedjaroude GA. (2007). Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi). Int Immunopharmacol. 7: 701-724. https://doi.org/10.1016/j.intimp.2007.01.008; PMid:17466905

Roth M, Fang L, Stolz D, Tamm M. (2019, Feb 1). Pelargonium sidoides radix extract EPs 7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells. PLoS One. 14 (2): e0210702. https://doi.org/10.1371/journal.pone.0210702; PMid:30707726 PMCid:PMC6358071

Seo YR, Patel DK, Shin WC, Sim WS, Lee OH, Lim KT. (2019). Structural elucidation and immune-enhancing effects of novel polysaccharide from Grifola frondosa. Biomed Res Int: 1-7. https://doi.org/10.1155/2019/7528609; PMid:31139649 PMCid:PMC6500627

Seo YR, Patel DK, Shin WC, Sim WS, Lee OH, Lim KT. (2019, Apr 16). Structural Elucidation and Immune-Enhancing Effects of Novel Polysaccharide from Grifola frondosa. Biomed Res Int: 7528609. https://doi.org/10.1155/2019/7528609; PMid:31139649 PMCid:PMC6500627

Suwannarach N, Kumla J, Sujarit K, Pattananandecha T, Saenjum C, Lumyong S. (2020, Apr 14). Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses. Molecules. 25 (8): 1800. https://doi.org/10.3390/molecules25081800; PMid:32295300 PMCid:PMC7221821

Ubiyvovk VM, Blazhenko OV, Gigot D, Penninckx M, Sibirny AA. (2006, Aug). Role of gamma-glutamyltranspeptidase in detoxification of xenobiotics in the yeasts Hansenula polymorpha and Saccharomyces cerevisiae. Cell Biol Int. 30 (8): 665-671. https://doi.org/10.1016/j.cellbi.2006.04.006; PMid:16857395

Xu S, Huo J, Lee KG, Kurosaki T, Lam KPJ Biol Chem. (2009, Mar 13). Phospholipase C gamma 2 is critical for Dectin-1-mediated Ca2+ flux and cytokine production in dendritic cells. 284 (11): 7038-7046. https://doi.org/10.1074/jbc.M806650200; PMid:19136564 PMCid:PMC2652331

Zakay-Rones Z, Thom E, Wollan T, Wadstein J. (2004, Mar-Apr). Randomized study of the efficacy and safety of oral elderberry extract in the treatment of influenza A and B virus infections. J Int Med Res. 32 (2): 132-140. https://doi.org/10.1177/147323000403200205; PMid:15080016

Zapater P, Gonzalez-Navajas JM, Such J, Frances R. (2015). Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis. World J Gastroenterol. 21: 11493-11501. https://doi.org/10.3748/wjg.v21.i41.11493; PMid:26556982 PMCid:PMC4631956





Original articles